Psilocybin mushrooms can contain a family of related tryptamine alkaloids rather than psilocybin alone. The best documented include psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin and norpsilocin. These compounds are chemically related, but their pharmacology is far less equally established. Psilocin has strong evidence as the main mediator of psychedelic effects through serotonin receptors including 5-HT2A. Baeocystin, norbaeocystin and aeruginascin remain active areas of preclinical research, and current evidence does not establish that they meaningfully change the human psychedelic experience.
The main tryptamine alkaloids in psilocybin mushrooms
When you examine the chemistry of a psilocybin-producing mushroom, psilocybin usually receives most of the attention because it is commonly one of the dominant measured tryptamines. Chemical analyses have also identified several closely related compounds at lower and highly variable concentrations.
The main compounds relevant to this group include the following.
| Compound | Chemical relationship | Current pharmacological evidence |
|---|---|---|
| Psilocybin | 4-phosphoryloxy-N,N-dimethyltryptamine | Prodrug converted to psilocin |
| Psilocin | 4-hydroxy-N,N-dimethyltryptamine | Main active serotonergic metabolite |
| Baeocystin | 4-phosphoryloxy-N-methyltryptamine | Minor alkaloid and biosynthetic intermediate |
| Norbaeocystin | 4-phosphoryloxytryptamine | Early biosynthetic intermediate |
| Norpsilocin | 4-hydroxy-N-methyltryptamine | Dephosphorylated analogue related to baeocystin |
| Aeruginascin | 4-phosphoryloxy-N,N,N-trimethyltryptamine | Quaternary ammonium analogue with limited pharmacological data |
Baeocystin and norbaeocystin differ from psilocybin mainly in how many methyl groups are attached to the terminal nitrogen. Aeruginascin carries one more methyl group than psilocybin and exists as a quaternary ammonium compound. These changes can alter receptor binding, membrane permeability, metabolism and access to the central nervous system.
You should therefore avoid treating all naturally occurring tryptamines as pharmacologically interchangeable. Small chemical differences can produce large biological differences.
The scientific history of this chemistry dates back decades. Albert Hofmann and colleagues reported psilocybin from Psilocybe mexicana in 1958 and published work on its chemical identity and synthesis later that year. Those studies established the foundation for later work on psilocybin, psilocin and related fungal tryptamines.
Psilocybin and psilocin and the prodrug relationship
If you are studying mushroom pharmacology, the distinction between psilocybin and psilocin is central.
Psilocybin contains a phosphate group at the 4-position of its indole ring. After administration, enzymes including alkaline phosphatase remove that phosphate group and produce psilocin. Psilocin can then reach the central nervous system and interact with serotonin receptors. Human and laboratory pharmacokinetic research consistently supports this prodrug relationship.
Psilocin acts at several serotonin receptor subtypes, with activation of the serotonin 2A receptor, written as 5-HT2A, strongly associated with its psychedelic effects. Research on serotonergic psychedelics has repeatedly identified 5-HT2A signaling as a major pharmacological mechanism behind their characteristic changes in perception and cognition.
This metabolic relationship also helps you interpret chemical analysis.
If a mushroom sample contains a high concentration of psilocybin, that value does not represent the amount of psilocin already present in the mushroom. Psilocybin can later be converted biologically into psilocin.
Chemical handling also affects the profile you measure. Psilocin is generally less chemically stable than phosphorylated psilocybin. Drying, heat, oxidation and storage conditions can therefore alter measured concentrations. Studies examining fungal samples have documented large changes in tryptamine profiles according to storage and processing conditions.
This is one reason research reports should tell you when samples were collected, how they were processed, how they were stored and which analytical method was used.
Baeocystin and norbaeocystin
Baeocystin and norbaeocystin are closely related to psilocybin and occupy defined positions within its fungal biosynthetic pathway.
Baeocystin is 4-phosphoryloxy-N-methyltryptamine. You can think of it chemically as the N-demethylated analogue of psilocybin. It was first isolated from Psilocybe baeocystis in the 1960s and has since been identified in multiple psilocybin-producing mushroom species.
Norbaeocystin has no methyl groups attached to the corresponding terminal nitrogen. Its systematic chemical description is 4-phosphoryloxytryptamine.
These compounds are especially interesting because fungal biosynthesis places them directly on the pathway leading to psilocybin.
What is baeocystin
Baeocystin is both a naturally occurring mushroom alkaloid and a biosynthetic precursor of psilocybin. The enzyme PsiM can add methyl groups sequentially to the nitrogen of norbaeocystin. The first methylation produces baeocystin and another methylation produces psilocybin.
Its close chemical similarity to psilocybin led to early speculation that it might have similar psychedelic activity.
Modern pharmacological data give you a more cautious picture.
In preclinical testing, baeocystin itself did not produce the mouse head-twitch response commonly used as an animal marker of 5-HT2A-mediated psychedelic-like activity. Research comparing psilocybin, baeocystin and related analogues found strong behavioral activity from psilocybin while baeocystin showed a markedly different profile.
Baeocystin can be dephosphorylated to norpsilocin. Norpsilocin has shown substantial activity at 5-HT2A receptors in laboratory assays. The pharmacology of the precursor, its conversion rate and the amount of norpsilocin reaching the brain all affect what that receptor result means biologically.
You therefore cannot infer a human psychedelic effect from chemical similarity alone.
What is norbaeocystin
Norbaeocystin occurs earlier in the biosynthetic sequence.
The fungal kinase PsiK phosphorylates 4-hydroxytryptamine to produce norbaeocystin. PsiM can then methylate norbaeocystin into baeocystin and subsequently psilocybin.
The dephosphorylated counterpart of norbaeocystin is 4-hydroxytryptamine.
Preclinical findings remain mixed and incomplete. A 2022 rat study reported that norbaeocystin did not trigger a head-twitch response under the tested conditions. A later pharmacological study found that its dephosphorylated product could activate 5-HT2A in cellular experiments. That 2024 study also reported behavioral findings suggesting that norbaeocystin may have biological actions separate from classic psychedelic-like activity, but those findings came from animal models and should not be treated as evidence of a human therapeutic effect.
At present, you can describe norbaeocystin confidently as a natural tryptamine alkaloid and a psilocybin biosynthetic intermediate. Statements about its clinical effects require much stronger human evidence.
Aeruginascin
Aeruginascin is chemically related to psilocybin but carries three methyl groups on its terminal nitrogen. Its chemical name is 4-phosphoryloxy-N,N,N-trimethyltryptamine.
It was first identified in Inocybe aeruginascens and has subsequently been reported in other psychoactive mushroom species, including some Psilocybe samples.
Its quaternary ammonium form gives it chemical properties that differ from psilocybin, baeocystin and psilocin. Charge and polarity affect the ability of a compound to cross lipid membranes, including the blood-brain barrier.
Aeruginascin can undergo dephosphorylation to form 4-hydroxy-N,N,N-trimethyltryptamine, commonly shortened to 4-HO-TMT. Laboratory receptor studies have found activity of this metabolite at several serotonin receptors, including 5-HT1A, 5-HT2A and 5-HT2B. Its receptor affinity and expected brain penetration differ from psilocin.
The evidence base remains small.
A review dedicated to aeruginascin found very limited pharmacological data and concluded that current evidence gives little support for a major direct contribution to a proposed mushroom entourage effect. Its dephosphorylated metabolite also appears less likely to cross the blood-brain barrier readily because of its permanent positive charge.
You should therefore be cautious with claims that aeruginascin reliably changes mood, produces a specific type of psychedelic experience or moderates the effects of psilocybin. Human controlled trials have not established those claims.
How psilocybin mushrooms make these alkaloids
The biosynthesis of psilocybin begins with the amino acid L-tryptophan and relies on a set of fungal enzymes identified through biochemical and genetic research.
Four enzymes receive particular attention.
- PsiD acts as an L-tryptophan decarboxylase
- PsiH acts as a monooxygenase
- PsiK acts as a kinase
- PsiM acts as an N-methyltransferase
A landmark 2017 study characterized these enzymes and demonstrated enzymatic psilocybin production from pathway precursors. Later biochemical and crystallographic work has clarified the individual reactions in much greater detail.
From tryptophan to 4-hydroxytryptamine
PsiD removes the carboxyl group from L-tryptophan to produce tryptamine.
PsiH then hydroxylates tryptamine at the 4-position of the indole ring, producing 4-hydroxytryptamine. Research also indicates that PsiD can act on 4-hydroxy-L-tryptophan in an alternate route to the same intermediate.
This intermediate is closely related to serotonin, which is 5-hydroxytryptamine. The position of the hydroxyl group differs.
From 4-hydroxytryptamine to norbaeocystin
PsiK phosphorylates 4-hydroxytryptamine.
The phosphate is added to the hydroxyl group, producing norbaeocystin. Research on PsiK has confirmed its role as the kinase responsible for this phosphotransfer step.
At this stage, you have the unmethylated phosphorylated tryptamine.
Norbaeocystin to baeocystin and psilocybin
PsiM performs successive N-methylation reactions.
Norbaeocystin receives one methyl group and becomes baeocystin. A second methylation produces psilocybin. S-adenosylmethionine supplies the methyl groups used by PsiM.
This sequence explains why norbaeocystin and baeocystin can appear alongside psilocybin in fungal samples. They are chemically connected to the same biosynthetic pathway.
A further PsiM methylation from psilocybin to aeruginascin has been proposed. Current enzymatic evidence does not establish that third methylation step as firmly as the reactions producing baeocystin and psilocybin. A biochemical study focused on PsiM specifically noted that formation of aeruginascin through an additional methyl transfer remained unproven.
That distinction is useful because pathway diagrams sometimes present all related compounds as if every enzymatic step has equal experimental support.
How mushroom alkaloid profiles are measured
If you want to know what a mushroom sample actually contains, laboratory analysis is required.
Visual appearance, strain name and species name cannot give you exact concentrations of psilocybin, psilocin, baeocystin, norbaeocystin or aeruginascin.
Modern studies commonly use high-performance liquid chromatography, abbreviated HPLC, or ultra-high-performance liquid chromatography paired with mass spectrometry.
HPLC separates compounds in an extract according to how they interact with the stationary phase and moving solvent system. A suitable detector then records the separated analytes.
Mass spectrometry adds information based on molecular mass and fragmentation patterns. When liquid chromatography is coupled to tandem mass spectrometry, researchers can separate related tryptamines and identify them with high analytical selectivity.
One large study of psychoactive fungal samples used validated UHPLC-MS/MS to quantify psilocybin, psilocin, baeocystin, norbaeocystin and aeruginascin. The researchers also examined different sections of fruiting bodies and tested how processing and storage affected concentrations.
HPLC paired with ultraviolet or diode-array detection can also quantify major alkaloids when appropriate reference standards and validated methods are used. Published research includes multiple chromatographic approaches for measuring psilocybin and psilocin in P. cubensis.
Reference standards are important
Chromatographic peaks need reliable identification.
Researchers can compare retention behavior and detector data with reference standards for known compounds. Mass spectrometry can provide another layer of identification from molecular ions and characteristic fragments.
This becomes particularly useful with minor alkaloids because their concentrations may be much lower than psilocybin.
A test designed only to quantify psilocybin and psilocin may tell you nothing about baeocystin or aeruginascin. When comparing published alkaloid profiles, you should check which compounds the analytical method was designed and validated to detect.
Why alkaloid profiles differ between samples
You should expect meaningful variation between mushroom samples.
Studies spanning different species and collections have repeatedly reported wide variation in tryptamine concentrations. One large analytical dataset described tryptamine concentrations as highly variable across fungal samples and identified psilocybin, psilocin and baeocystin in differing proportions.
Several factors can contribute.
- Species
- Genetic line
- Individual fruiting body
- Developmental stage
- Cap and stipe tissue
- Cultivation conditions
- Drying conditions
- Storage temperature
- Storage duration
- Oxidative degradation
- Extraction protocol
- Analytical method
You can see variation even within one mushroom.
Research comparing caps, stipes, mycelium and other fungal tissues has found different alkaloid concentrations according to the section analyzed. Storage experiments have also shown measurable losses or shifts over time.
Chemical instability is especially relevant to psilocin. Oxidation can lower the amount recovered during analysis. A study conducted months after collection can therefore produce a different profile from one performed shortly after drying.
This makes sample documentation a core part of alkaloid research. A concentration figure has limited scientific use if you do not know what was sampled and how it was handled.
Do minor alkaloids affect the psychedelic experience
Current evidence does not provide a reliable human answer.
Baeocystin, norbaeocystin, aeruginascin and related tryptamines have chemical and pharmacological features that make them scientifically interesting. Some of their dephosphorylated metabolites can interact with serotonin receptors in laboratory systems. Animal research has also identified behavioral effects that differ from those of psilocybin.
Those observations do not establish a distinct subjective effect in humans.
For example, baeocystin is closely related to psilocybin chemically, yet animal experiments have failed to show the same head-twitch response produced by psilocybin. Norbaeocystin has shown biological activity in some animal tests without the same psychedelic-like behavioral marker. Aeruginascin has limited pharmacological data and uncertain central nervous system exposure.
Human studies directly comparing purified psilocybin with defined mixtures of psilocybin and minor mushroom alkaloids remain sparse.
You should therefore separate three claims.
First, psilocybin mushrooms contain several related tryptamines. That is well supported.
Second, some minor tryptamines or their metabolites have measurable pharmacological activity. Preclinical evidence supports this for certain compounds.
Third, those compounds produce a predictable change in the human psychedelic experience when combined with psilocybin. Current evidence does not establish that claim.
Is there an entourage effect in psilocybin mushrooms
The proposed entourage effect refers to the idea that multiple compounds in whole mushrooms could interact to produce pharmacological effects different from purified psilocybin alone.
It remains a hypothesis in psilocybin mushroom research.
Reviews have proposed several possible contributors, including baeocystin, norbaeocystin, norpsilocin, aeruginascin and other fungal metabolites. The concept is biologically plausible enough to study because some of these compounds have activity at serotonergic targets or can be metabolized into receptor-active compounds.
Direct human evidence is currently inadequate for saying that a clinically meaningful entourage effect occurs.
The aeruginascin literature illustrates the problem. The compound has been discussed as a possible contributor to differences between mushroom preparations, yet focused pharmacological review found limited evidence for a major direct effect and raised questions about brain penetration.
Baeocystin presents another example. Its metabolite norpsilocin can activate 5-HT2A receptors in laboratory systems, while baeocystin itself did not produce the expected psychedelic-like response in mice.
The most defensible scientific position is that whole mushrooms contain chemically diverse tryptamine profiles and some minor compounds have biological activity. Controlled human studies are still needed to determine if those compounds alter the acute or therapeutic effects associated with psilocybin.
This line of research may become useful for psychedelic science because it can clarify which biological effects come from psilocin exposure and which, if any, depend on other fungal constituents.
Conclusion
Several basic questions remain open.
You do not yet have strong human dose-response data for baeocystin, norbaeocystin or aeruginascin.
You do not have established human concentration thresholds showing when these compounds would meaningfully contribute to pharmacological effects.
You also do not have strong controlled clinical evidence comparing purified psilocybin with chemically characterized whole-mushroom preparations containing defined concentrations of minor tryptamines.
The biosynthetic pathway is much better established. PsiD, PsiH, PsiK and PsiM have all been characterized, and researchers can explain how norbaeocystin, baeocystin and psilocybin are chemically connected.
Pharmacology has further to go.
The 2024 study comparing psilocybin, baeocystin, norbaeocystin and aeruginascin found shared metabolic features and several differences in blood-brain-barrier models, receptor activity and rodent behavior. The authors identified norbaeocystin as particularly interesting for further study while stressing that the findings came from preclinical systems.
This is also why measured alkaloid profiles should be reported directly when research uses fungal preparations. A species or strain name cannot tell you the exact concentration of each tryptamine in a specific sample.
As you examine how fungal alkaloid profiles relate to psychedelic research, we at Rose Hill Life Sciences work as a psychedelic research organization focused on the production and research of Psilocybe cubensis at the intersection of science and therapeutic integration, including our Massachusetts research work where chemical characterization and reproducible fungal research are relevant to studying psilocybin and related compounds.
For scientific interpretation, each alkaloid should be assessed on its own evidence. Psilocybin and psilocin have the strongest pharmacological record. Baeocystin, norbaeocystin, norpsilocin and aeruginascin add chemical complexity to psilocybin-producing mushrooms, while their contribution to human effects remains incompletely defined. Better analytical profiling and controlled pharmacology can clarify those roles as the evidence develops.
Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.
